MASSACHUSETTS GENERAL HOSPITAL
Department of Pharmacy
Department of Nursing
Critical Care
Generic Name: |
Phytonadione, Vitamin K |
||||||||||
Trade Name: |
AquaMephyton® |
||||||||||
Action: |
Promotes hepatic synthesis of coagulation factors II, VII, IX and X |
||||||||||
Indications: |
Prevention and treatment of hypoprothrombinemia caused by coumarin derivative-induced or drug-induced vitamin K deficiency Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K |
||||||||||
Administration Guidelines: |
|||||||||||
Usual Dosage Range and Route: |
Management of elevations in INR secondary to warfarin The response to vitamin K 1 administered subcutaneously (SC) is less predictable compared to oral vitamin K 1 and is sometimes delayed. Oral administration has the advantages of safety and convenience over parenteral routes and should be preferred when indicated.
Intravenous doses of vitamin K should be administered over 20 minutes Maximum infusion rate is 1mg/min |
||||||||||
Standard Concentration: |
Each dose mixed in 100 ml of 0.9% saline or D5W Micro-Infusion Administration: Each dose mixed in 10 ml in a 60ml syringe “For ICU Only” |
||||||||||
Special Considerations: |
Severe reactions including: hypersensitivity, anaphylaxis, shock, cardiac arrest and/or respiratory arrest have occurred during or immediately after IV administration (even with proper dilution and rate of administration). Allergic reactions have also occurred with IM and subcutaneous injections. Intravenous phytonadione should be restricted to those situations where the subcutaneous and oral routes are not feasible and the risk is justified. Subcutaneous administration is recommended for patients with obstructive jaundice and/or biliary fistulas since the presence of bile salts is necessary for the absorption of phytonadione from the GI tract. Monitor: PT, INR |
||||||||||
Precautions and Side Effects: |
Contraindicated in patients with hypersensitivity to phytonadione Anaphylaxis Hypotension, cardiac arrest Dyspnea, respiratory arrest Skin lesions (primarily with IM administration), flushing, cyanosis Anaphylaxis Anemia, thrombocytopenia |
||||||||||
Mesac approved 6/19/07